SignaBlok, Inc. has been awarded a contract from the Defense Advanced Research Projects Agency (DARPA) to introduce company’s approach to the prevention and treatment of sepsis (blood poisoning), and to establish proof-of-concept in vivo. SignaBlok’s approach targets an inflammation amplifier, a specific receptor called TREM-1, which has been shown to improve survival in animal models of sepsis. The company’s peptide inhibitors that are developed using a new model of cell signaling, known as th...